Yüklüyor......
Bromocriptine in type 2 diabetes mellitus
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased pl...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Medknow Publications
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3152192/ https://ncbi.nlm.nih.gov/pubmed/21847449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.83058 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|